Clots are AstraZeneca's latest curse

The British laboratory made headlines in November when it claimed its jab could match the 90 percent effectiveness of the rival and much more expensive Pfizer/BioNTech jab, which has to be kept at extremely low temperatures.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news